XERSXeris Biopharma Holdings, Inc.
Pharmaceutical Preparations
- Revenue
- $292M
- 44% YoY
- Operating margin
- 8.5%
- 151% YoY
- EBITDA
- $26M
- 181% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- 5.0×
- $131M net debt
- AI in 10-K
- —
Red flags 0 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear52× net incomeCash flow under 80% of net income
- Dilutive SBCClear8% of revenueOver 10% of revenue
- Payouts exceed cash flowClear0% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear6% of assetsOver 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $50M | $110M | $164M | $203M | $292M | 44% |
| Operating income | −$115M | −$82M | −$44M | −$34M | $25M | 174% |
| Net income | −$123M | −$95M | −$62M | −$55M | $554K | 101% |
| Operating cash flow | −$96M | −$103M | −$47M | −$37M | $29M | 177% |
| Capex | $1M | — | — | — | — | |
| Stock-based comp | $11M | $12M | $11M | $18M | $22M | 22% |
Deal filings
None.
13D filers
None on file.
Insider trading
- Open-market buys, 12 mo
- $0 · 0
- Open-market sells, 12 mo
- $595K · 4
- Net
- −$595K
Pay vs performance
| Year | CEO total comp | Comp actually paid | TSR (indexed) | Peer TSR |
|---|---|---|---|---|
| FY2025 | $5M | $12M | 160 | 125 |
| FY2024 | — | — | 69 | 93 |
| FY2023 | $2M | $3M | 48 | 94 |
| FY2022 | $3M | $1M | 27 | 90 |
| FY2021 | $4M | $2M | 60 | 100 |